Results 251 to 260 of about 43,902 (289)

Clinical and biochemical efficacy zoledronic acid and denosumab combination: focus serum inflammatory factor level (serum ifcs), bone gla protein (bgp), and bone turnover markers b-collagen degradation product (b-ctx), and procollagen type 1 n-terminal propeptide (p1np)

Lingyan Kong, Jun Ma
openalex   +1 more source

Effect of denosumab combination with proximal femoral nail antirotation surgery in elderly patients with intertrochanteric femoral fractures: A comparative study. [PDF]

Bone Rep
Lu X, Zhu J, Zheng B, Wang J.
europepmc   +1 more source

Metaphyseal band fractures in pediatric patients treated with denosumab

Rodrigo Montero-Lopez, Karissa Ludwig, Benjamin Jacobs, Alexander D Chesover, Fahd Alshammri, Manuela Mayrhofer, Alexandra Blaschitz, Wayne Nicholls, Craig F Munns, Leanne M Ward, Wolfgang Hogler, Rodrigo Montero-Lopez, Karissa Ludwig, Benjamin Jacobs, Alexander D Chesover, Fahd Alshammri, Manuela Mayrhofer, Alexandra Blaschitz, Wayne Nicholls, Craig F Munns, Leanne M Ward, Wolfgang Hogler   +21 more
openalex   +1 more source

Effectiveness of Sequential Treatment with Zoledronic Acid Following Discontinuation of Denosumab in Osteoporosis: A Narrative Review. [PDF]

Drug Des Devel Ther
Ouyang H, Yang F, Wei W, Wang W.
europepmc   +1 more source

Zoledronic acid and denosumab are associated with similar fracture incidence and mortality in patients with type 2 diabetes: a population-based cohort study. [PDF]

Front Endocrinol (Lausanne)
Rouach V, Gortler H, Greenman Y, Chodick G, Goldshtein I.   +4 more
europepmc   +1 more source

Multiple Treatment Analysis of Aneurysmal Bone Cysts in Mobile Spine. [PDF]

Global Spine J
Liu F, Wang B, Liu X, Wu F, Zhou H, Dang L, Li Y, Tang Y, Liu X, Hu P, Li Z, Wei F, Liu Z.   +12 more
europepmc   +1 more source

From Bone Health to Lifespan: Pleiotropic Effects of Antiresorptive Agents. [PDF]

Endocrinol Metab (Seoul)
Kim KJ.
europepmc   +1 more source

Management of bone metastases in refractory prostate cancer – role of denosumab

, 2012
Paller CJ, Songjiang Chen
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone

Nature Reviews Rheumatology, 2023
Serge Ferrari
exaly   +2 more sources